Latest News

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

If you are wondering whether Omnicell at around US$46 is a bargain or a value trap, this article will walk you through what the current price might be implying. The stock has had a mixed run, with a 7.8% decline over the last week, a 2.0% gain over the past month, and returns of 2.0% year to date and 5.0% over the last year. It is still sitting well below its 3 year and 5 year levels, with declines of 21.0% and 65.2% over those periods. Recent coverage around Omnicell has focused on its role...

What Allstate’s Latest Figures Tell Investors Allstate (ALL) is back in focus as investors reassess the insurer’s recent share performance and financial profile, with the stock last closing at $201.77 and showing mixed returns across different time frames. Over the past week, the share price return was about 3.6%, while the month return was a decline of roughly 1%. Over the past 3 months, the stock shows a gain of about 3.6%, and the 1 year total return is close to 7.8%. Looking at a longer...

If you are wondering whether Builders FirstSource at around US$118 still offers solid value, or if most of the opportunity is already priced in, this article is designed to help you assess that for yourself. The stock has a 7 day return of 1.1%, a 30 day and year to date return of 13.3%, but a 1 year return showing a 27.5% decline, so recent moves look very different depending on the time frame you focus on. Recent market attention has been shaped by ongoing interest in US housing and...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

ABIVAX Société Anonyme (ENXTPA:ABVX) is drawing attention after reporting that its lead drug candidate obefazimod showed efficacy with a clean safety profile in a Phase 3 ulcerative colitis trial, alongside plans for further pivotal studies. See our latest analysis for ABIVAX Société Anonyme. The recent Phase 3 ulcerative colitis result and takeover speculation arrive after a mixed stretch for the share price, with a 1 day share price return of 2.99%, a 30 day share price return decline of...

OSL Group (SEHK:863) has launched a sizeable equity raise, combining a HK$1.56b private placement and follow on offering to fund its stablecoin and payments push and broader digital asset platform expansion. See our latest analysis for OSL Group. That equity raise lands after a sharp 15.56% 7 day share price decline and a 10.48% year to date share price fall, even though the 1 year total shareholder return is 58% and the 3 year total shareholder return is very large at roughly 3x. If this...

Franklin Resources (BEN) is back in focus after reporting first quarter 2026 earnings that topped Wall Street expectations, supported by strong long term net inflows, growth in alternatives, and record ETF assets under management. See our latest analysis for Franklin Resources. The earnings beat, ongoing buybacks and the launch of the AI powered Intelligence Hub with Microsoft arrive as the shares trade at US$27.0, with a 30 day share price return of 13.45% and a 1 year total shareholder...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...

Q3 earnings miss and market reaction Masco (MAS) reported a disappointing Q3, with revenue down 3.3% year on year and adjusted operating income and EBITDA below analyst expectations, with management pointing to challenging market conditions as a key headwind. See our latest analysis for Masco. Despite the weak Q3, Masco’s share price has shown positive short term momentum, with a 30 day share price return of 5.55% and a 3 year total shareholder return of 31.90%, although the 1 year total...

Rithm Capital (RITM) has put up a steady run of numbers heading into FY 2025, with third quarter revenue at US$943 million and basic EPS of US$0.36, alongside trailing twelve month revenue of about US$4.0 billion and EPS of US$1.47. The company has seen quarterly revenue move between US$646 million and US$1.3 billion over the last six reported periods, with basic EPS ranging from US$0.07 to US$0.54. This sets a clear backdrop for how investors might read the current US$10.95 share price...

Some investors may be wondering if Broadcom's share price still offers value after a large multi year run, or if most of the upside is already reflected in the stock. The shares closed at US$320.33, with a 3.7% decline over the last 7 days and a 7.9% decline over the last 30 days. Over the last 1 year the return sits at 45.3%, and the 5 year return is around 7x. Recent news coverage has focused on Broadcom's role as a major semiconductor and infrastructure software player and how that...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

RPC (RES) has just posted its FY 2025 third quarter scorecard, reporting revenue of $447.1 million and basic EPS of $0.06. This puts fresh numbers on the table after a run of mixed earnings over the past year. The company’s revenue has moved from $364.2 million in FY 2024 Q2 to $337.7 million in Q3 and $335.4 million in Q4, then to $332.9 million, $420.8 million and now $447.1 million through FY 2025. Over the same stretch, quarterly EPS shifted from $0.15 to $0.09, $0.06, $0.06, $0.05 and...

Spire Inc. reported past first‑quarter 2026 results with sales of US$762.2 million and net income of US$95 million, alongside announcing the redemption of all 5.90% Series A preferred shares and affirming its quarterly common dividend of US$0.825 per share. Beyond the headline earnings growth, Spire’s decision to retire its higher-cost preferred stock while pursuing an US$11.2 billion long-term capital plan underpins a clearer, streamlined capital structure and reinforces management’s focus...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

With its stock down 10.0% over the past three months, it is easy to disregard Eris Lifesciences (NSE:ERIS). It is...

Waters Corporation (NYSE:WAT) has completed its acquisition of Wyatt Technology as part of a broader shift in its business strategy. The company has also announced a planned merger with BD Biosciences, signaling a push deeper into large molecule applications. These moves are expected to reshape Waters' role in the biotech and life sciences tools space, with implications for its future operations. Waters, trading at $378.95, is responding to a period of mixed share performance with an active...

At its Perform 2026 user conference held in late January, Dynatrace unveiled Dynatrace Intelligence, fusing deterministic and agentic AI, alongside expanded multi-cloud integrations and next-generation real user monitoring capabilities. An interesting aspect of these launches is Dynatrace’s push to position its platform as a control plane for AI in production, aiming to automate complex IT and business operations. We’ll now examine how Dynatrace Intelligence’s focus on agentic AI and...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

If you are wondering whether Newell Brands' current share price reflects its true worth, you are not alone. This article walks through what the latest data says about value. The stock most recently closed at US$4.40, with returns of 0.9% over 7 days and 18.3% over both the last 30 days and year to date, against a longer term record that includes a 52.0% decline over 1 year, 67.4% over 3 years and 79.4% over 5 years. Those mixed returns sit against a backdrop of ongoing attention on Newell...

Twist Bioscience (NasdaqGS:TWST) reported its twelfth consecutive quarter of revenue growth. The company raised its full year outlook, citing momentum in AI enabled DNA synthesis and wider use of its platform. Management also reiterated a focus on progressing toward profitability alongside scaling the business. Twist Bioscience, a provider of synthetic DNA and related tools, operates at the intersection of biotechnology and AI driven research. Its platform supports customers in areas such...

GE Vernova (NYSE:GEV) has entered a wide-ranging alliance with Xcel Energy covering gas and wind turbine deployments, grid projects, and joint R&D in areas such as artificial intelligence. The company launched its GridBeats APS grid modernization platform, aimed at improving efficiency, resilience, and capacity across power networks. GE Vernova also completed the full acquisition of Prolec GE, integrating additional grid equipment capabilities into its portfolio. For you as an investor...

Key Insights S H Kelkar's significant insider ownership suggests inherent interests in company's expansion A total of 4...